Mineralys Therapeutics (MLYS) Amortizatization of Intangibles (2022 - 2026)
Quarterly results put Amortizatization of Intangibles at $4.6 million for Q1 2026, up 342.16% from a year ago — trailing twelve months through Mar 2026 was $13.5 million (up 69.45% YoY), and the annual figure for FY2025 was $9.9 million, up 5.04%.
Mineralys Therapeutics has reported Amortizatization of Intangibles over the past 5 years, most recently at $4.6 million for Q1 2026.
- Amortizatization of Intangibles reached $4.6 million in Q1 2026 per MLYS's latest filing, up from $4.2 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $4.6 million in Q1 2026 and bottomed at $239000.0 in Q3 2022.
- Median Amortizatization of Intangibles over the past 5 years was $2.1 million (2023), compared with a mean of $2.1 million.
- The largest annual shift saw Amortizatization of Intangibles surged 720.92% in 2023 before it plummeted 58.31% in 2025.
- Over 5 years, Amortizatization of Intangibles stood at $410000.0 in 2022, then surged by 403.9% to $2.1 million in 2023, then crashed by 35.29% to $1.3 million in 2024, then skyrocketed by 214.73% to $4.2 million in 2025, then increased by 9.91% to $4.6 million in 2026.
- Business Quant data shows Amortizatization of Intangibles for MLYS at $4.6 million in Q1 2026, $4.2 million in Q4 2025, and $2.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - | 4.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.63 Mn |
| Mar 31, 2026 | 4.63 Mn |
| Dec 31, 2025 | 4.21 Mn |
| Dec 31, 2025 | 4.21 Mn |
| Sep 30, 2025 | 2.40 Mn |
| Sep 30, 2025 | 2.40 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 2.71 Mn |
| Sep 30, 2024 | 2.71 Mn |
| Jun 30, 2024 | 2.85 Mn |
| Jun 30, 2024 | 2.85 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | 2.07 Mn |
| Dec 31, 2023 | 2.07 Mn |
| Sep 30, 2023 | 1.96 Mn |
| Sep 30, 2023 | 1.96 Mn |
| Jun 30, 2023 | 1.98 Mn |
| Jun 30, 2023 | 1.98 Mn |
| Mar 31, 2023 | 855,000.00 |
| Mar 31, 2023 | 855,000.00 |
| Dec 31, 2022 | 410,000.00 |
| Dec 31, 2022 | 410,000.00 |
| Sep 30, 2022 | 239,000.00 |
| Sep 30, 2022 | 239,000.00 |